Ultragenyx Stock: Pipeline Setback in 2026 – Can Strong Revenue Offset Clinical Failure?
- Why Did Ultragenyx Stock Crash in December 2025?
- Revenue Strength: A Silver Lining?
- 2026 Make-or-Break Events
- Should You Buy, Hold, or Sell Ultragenyx?
- Ultragenyx FAQ
Ultragenyx (NASDAQ: RARE) faces a turbulent start to 2026 after its Phase III drug setrusumab flopped, sending shares down 30% in a month. Yet, the biotech’s robust 2025 revenue ($672M–$674M, up 20% YoY) and cash reserves ($735M) offer a lifeline. With critical FDA decisions looming—like DTX401 for GSDIa and UX111 for MPS IIIA—investors are torn: Is this a buying opportunity or time to bail? Here’s our deep dive.
Why Did Ultragenyx Stock Crash in December 2025?
The nosedive began when Ultragenyx announced that setrusumab (UX143), its experimental treatment for brittle bone disease (Osteogenesis imperfecta), failed both Phase III trials (Orbit and Cosmic). The drug showedreduction in fractures versus placebo and couldn’t outperform standard bisphosphonates. Cue panic selling—shares tanked to $24.21, and law firm Levi & Korsinsky launched a probe. Ouch. Even worse? This came after a Q3 2025 earnings miss ($1.81 loss per share vs. $1.23 expected). Talk about bad timing.
Revenue Strength: A Silver Lining?
Despite the clinical flop, Ultragenyx’s commercial engine is humming. Key products delivered in 2025:
- Crysvita (for rare bone disorders): $480M–$482M (+17% YoY)
- Dojolvi (fatty acid metabolism): $95M–$97M (+9% YoY)
2026 Make-or-Break Events
Ultragenyx’s fate hinges on three near-term catalysts:
- DTX401 (GSDIa): FDA decision (PDUFA) expected Q3 2026.
- UX111 (MPS IIIA): Biologics License Application (BLA) resubmission early 2026.
- GTX-102 (Angelman syndrome): Phase III data due H2 2026.
Should You Buy, Hold, or Sell Ultragenyx?
Here’s the rub: If you’re bullish, the current dip looks tasty. Revenue growth is legit, and the pipeline isn’t a total write-off. But if you’re risk-averse? Steer clear. This stock swings harder than a pendulum on Red Bull. Personally, I’d wait for DTX401’s FDA verdict—it’s the next big binary event.
Ultragenyx FAQ
What caused Ultragenyx’s stock drop?
The failure of setrusumab in Phase III trials triggered a 30% sell-off in December 2025.
How much cash does Ultragenyx have?
$735 million as of end-2025, per their preliminary report.
Is Crysvita still growing?
Yes—2025 sales hit $482M, up 17% year-over-year.
